Elicio Therapeutics reports FY2023 net loss $35.2M; cash boosted by $6M private placement

Elicio Therapeutics, Inc.

Net loss of $35.2M for FY2023 vs $28.2M in FY2022; diluted EPS -$6.96 vs -$89.27 (reverse-merger impact).
Cash and cash equivalents $12.9M at Dec 31, 2023; $6.0M private placement closed in March 2024.
ELI-002 2P Phase 1a data in Nature Medicine: 84% T cell response, 24% biomarker clearance, median RFS 16.33 months.
Phase 2 randomized trial of ELI-002 7P in PDAC started; enrollment expected to complete Q4 2024.
Initial clinical data from ELI-002 7P Phase 1 trial anticipated in Q2 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Elicio Therapeutics, Inc. reported the year ending December 31, 2023 results: net income Net loss for 2023 was $35.2 million, EPS Net loss per share for 2023 was $6.96.

Period: the year ending December 31, 2023
Net income: Net loss for 2023 was $35.2 million
EPS: Net loss per share for 2023 was $6.96
Result: reported results

Exact text from the filing

Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2023 and provided corporate updates.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001601485-24-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.